Barclays
SER icon

Barclays’s Serina Therapeutics SER Stock Holding History

Barclays’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,169
Closed -$64K – 5066
2021
Q2 		$64K Hold
1,169
– – ﹤0.01% 4027
2021
Q1 		$67K Hold
1,169
– – ﹤0.01% 4135
2020
Q4 		$62K Hold
1,169
– – ﹤0.01% 4325
2020
Q3 		$33K Sell
1,169
-173
-13% -$6.17K ﹤0.01% 4773
2020
Q2 		$45K Sell
1,342
-27
-2% -$795 ﹤0.01% 4979
2020
Q1 		$44K Buy
1,369
+764
+126% +$35.9K ﹤0.01% 5306
2019
Q4 		$39K Buy
605
+304
+101% +$16.4K ﹤0.01% 5814
2019
Q3 		$21K Sell
301
-92
-23% -$8.73K ﹤0.01% 6203
2019
Q2 		$50K Buy
393
+253
+181% +$34.3K ﹤0.01% 6098
2019
Q1 		$19K Buy
140
+133
+1,900% +$19.4K ﹤0.01% 6381
2018
Q4 		$0 Buy
+7
New +$890 ﹤0.01% 7403

Other funds holding SER

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Barclays's SER Position: Q3 2021 in Review

Barclays sold out of Serina Therapeutics (SER) in Q3 2021, closing a stake of 1,169 shares — an estimated $64K sold.

Barclays first reported a position in SER in Q4 2018 and held it in 11 quarters. The position peaked at $67K in Q1 2021. 31 funds tracked by Wall St. Rank hold SER as of Q3 2021.

  • Barclays reported no remaining Serina Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Barclays sold 1,169 Serina Therapeutics shares in Q3 2021, an estimated $64K.
  • Barclays first reported a position in Serina Therapeutics in Q4 2018 and held it in 11 quarters.
  • Barclays's Serina Therapeutics position peaked at $67K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Serina Therapeutics as of Q3 2021.

Based on Barclays's 13F filing for Q3 2021, filed 9 Nov 2021.